CM Shinde presents Ratan Tata with ‘Udyog Ratna’, calls him an institution

Maharashtra Chief Minister Eknath Shinde on Sunday hailed industrialist Ratan Tata, the first-ever recipient of the ‘Udyog Ratna’ award instituted by the state government, as an “institution”.
Shinde also said industries in Maharashtra are the main strength of the growth engine.
He was speaking at the Udyog Puraskar 2023 distribution ceremony here where he praised Ratan Tata.
The ‘Udyog Ratna’ award was presented to the 85-year-old chairman emeritus of Tata Sons by Shinde and Deputy CMs Devendra Fadnavis and Ajit Pawar at the industrialist’s home in south Mumbai on Saturday.
On Sunday, Adar Poonawalla of Serum Institute was honoured with the Udyog Mitra award while the Udyogini award was given to Gauri Kirloskar. The best Marathi businessman award was bestowed upon Vilas Shinde, the MD of Sahyadri Farmers’ Producers Company.
None of us have seen God, but it is believed that God is everywhere. We have selected a ‘dev manoos’ (Godly person) like Ratan Tata for the (first ever) Udyog Ratna award. Tata means trust and quality assurance, and the company has always demonstrated its social connect, the chief minister said.
Industries in Maharashtra are the main strength of the growth engine. The state has thus decided to acknowledge the contribution of the industries through such awards, Shinde said.
The chief minister said he signed investment agreements worth Rs 1.37 lakh crore during his visit to Davos last year.
“Out of them, 85 per cent of agreements have progressed further. Maharashtra has once again topped the chart of attracting FDI (Foreign Direct Investments), he claimed.
Shinde said all industries, traders, businessmen and various chambers of commerce should form a high-power committee to prepare a blueprint for the next 25 years of the state’s progress.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre